Polymorphism of the Lipoprotein Lipase Gene and Risk of Atherothrombotic Cerebral Infarction in the Japanese

DOI Web Site 被引用文献2件
  • Yumi Shimo-Nakanishi
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
  • Takao Urabe
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
  • Nobutaka Hattori
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
  • Yoshiro Watanabe
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
  • Takehiko Nagao
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
  • Masayuki Yokochi
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
  • Makoto Hamamoto
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
  • Yoshikuni Mizuno
    From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).

説明

<jats:p> <jats:italic>Background and Purpose</jats:italic> —Lipid and lipoprotein abnormalities have been implicated in the pathogenesis of ischemic cerebrovascular disease and atherosclerosis. Lipoprotein lipase (LPL) plays an important role in plasma lipoprotein metabolism. Several studies have recently reported the presence of a relationship between Ser447Stop mutation of LPL and coronary artery disease. Other polymorphisms ( <jats:italic>Hin</jats:italic> dIII and <jats:italic>Pvu</jats:italic> II) of the LPL gene have already been shown to correlate significantly with dyslipidemia. We investigated whether these polymorphisms are associated with increased risk of ischemic cerebrovascular disease (CVD). </jats:p> <jats:p> <jats:italic>Methods</jats:italic> —We recruited 177 CVD patients (atherothrombotic infarction, n=71; cardioembolic infarction, n=30; lacunar infarction, n=76) and 177 healthy control subjects. Subjects were genotyped for the Ser447Stop mutation and for <jats:italic>Hin</jats:italic> dIII/ <jats:italic>Pvu</jats:italic> II restriction fragment length polymorphisms of the LPL gene, and the findings were investigated for associations with the clinical subtypes of CVD and with lipid levels. </jats:p> <jats:p> <jats:italic>Results</jats:italic> —The Ser447Stop mutation correlated significantly with CVD (0.107 versus 0.158; <jats:italic>P</jats:italic> =0.035). For the <jats:italic>CG+GG</jats:italic> versus <jats:italic>CC</jats:italic> genotype, the odds ratio between control subjects and CVD patients with atherothrombotic infarction was 0.42 (95% CI, 0.18 to 0.99) ( <jats:italic>P</jats:italic> =0.046). Serum HDL cholesterol and triglyceride levels did not correlate significantly with the Ser447Stop genotype. <jats:italic>Hin</jats:italic> dIII polymorphism correlated significantly with CVD (0.234 versus 0.169; <jats:italic>P</jats:italic> =0.031), but the frequency of <jats:italic>Pvu</jats:italic> II polymorphism was not significantly different between groups. </jats:p> <jats:p> <jats:italic>Conclusions</jats:italic> —Our results suggest that the Ser447Stop mutation of the LPL gene is a novel genetic marker for low risk of atherothrombotic cerebral infarction. </jats:p>

収録刊行物

  • Stroke

    Stroke 32 (7), 1481-1486, 2001-07

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ